The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.